Build it up gradually: Increase slowly over a week or two
Semaglutide influences glucose metabolism, insulin secretion, and appetite regulation
According to Grand View Research, the semaglutide (Wegovy) segment held 60.70% of the global GLP-1 weight loss drug market share in 2024
Keep a glass of water on your nightstand and stay hydrated before bed
Medicare Part D coverage for Wegovy (oral and injectable) begins January 2027, with an interim program starting July 2026
Patients should contact their GP if they experience significant deterioration in blood glucose control (persistent readings above 15 mmol/L, symptoms of hyperglycaemia such as excessive thirst or urination), unexplained weight changes, or any concerning symptoms after stopping treatment